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This paper argues that pharmaceutical manufacturing in Kenya did not 
establish i t s e l f behind a protect ionist barr i e r . At the same time, the industry 
displays most of the features associated with the kind of manufacturing ac t i v i t y 
which requires government intervention in order to locate in a country l ike 
Kenya. This apparent paradox is explained primarily in terms of market 
imperfections in the pharmaceuticals sector and the implications of such a 
situation fo r government pol icy are touched on b r i e f l y . 
Trade Pol icy as a Determinant of Industrial Structure: The Case of the 
Kenyan Pharmaceutical Industry. 
1. Introduction 
In most developing countries the des i rab i l i t y of d ivers i f i ca t ion into 
manufacturing a c t i v i t i e s is taken as axiomatic. I t is held that the nurture 
of industry w i l l provide an important source of dynamic growth within the 
economy and that the process of industr ia l izat ion w i l l transmit valuable s k i l l s , 
discipl ines and technologies to the indigenous economy which would otherwise 
have to be imported. I t is further argued that involvement in the international 
economy on the basis of importing manufactures and exporting primary products 
is inimical to development prospects as a result of unfavourable foreign demand 
e l a s t i c i t i e s , secularly declining terms of trade and f luctuating foreign 
exchange receipts from exporting. 
Such considerations have led many developing countries to seek a set 
of po l i c i es which discriminate in favour o f f l edge l ing industries and guarantee 
the ir p r o f i t a b i l i t y . The opmrr.sn of many developing economies, such as Kenya's 
has made trade pol icy a central ingredient in the intervent ionist mix that 
has been applied. The industr ia l sector is linked to trade considerations 
both on the import and the export sides. On the import s ide, this arises from 
the domestic unavai labi l i ty or ine las t i c i t y of certain inputs. Such inputs 
include physical capital,, human capital and raw materials. On the export s ide, 
the links arise from the need to acquire purchasing power over imports, from 
specia l izat ion advantages ( internal and external economies of sca le ) and from 
s ize l imitations of the domestic market, which may take the form of small 
population s ize or of low income per head or both. 
Where the industrial sectors of poor countries have been very small, 
or have scarcely existed, the f i r s t phase of industr ia l izat ion has inevitably 
involved import prevention and the substitution of those imports with domestic 
production. This process of import substitution and some of i t s less desirable, 
and possibly unforeseen, consequences have been wel l documented ( f o r example, 
the L i t t l e e t a l . volume (1970) and hardly require elaboration.'1 ' B r i e f l y , the 
1. For a treatment of these issues in a Kenyan context see Power (19 72) 
and Phelps and Wasow. 
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crit ic isms of the import substitution strategy l i e in the fact that i t has 
frequently been used excessively and a rb i t ra r i l y , part ly because the notion 
that a l l industry i s 'des irable ' has pervaded the thinking of pol icy makers. 
Another part of the problem has been that import prevention has often been 
employed to serve the exigencies of short-term foreign exchange shortages as 
much as to enable a planned and spec i f i ed industr ia l structure to emerge. 
The import substitution pol icy package usually consists in se l ec t i ve 
and highly d i f f e rent ia ted taxes on imports ( o r se l ec t i ve quotas and outright 
2 
bans) combined with over-valued domestic currency. The currency over-valuation 
allows the r e l a t i v e l y cheap importation of capi ta l goods and raw materials 
and the taxes and/or quantitative restr ic t ions on selected consumer good 
imports guarantee the p r o f i t a b i l i t y of domestic production of these items at 
output prices above those prevai l ing in world markets. Amongst the more 
deleterious e f f e c t s ( in economic terms) of these measures are excessive 
pro l i f e ra t ion of d i f f e rent ia ted product l ines , a tendency towards greater 
capital intensity in production, the sustenance of excess capacity in the face 
of high p r o f i t rates, the creation of monopolistic and o l i gopo l i s t i c posit ions 
with the i r attendant i n e f f i c i enc i e s , growing import dependency in the manufac-
turing sector and an inherent bias against exporting. When protection i s 
granted to a part icular ac t i v i t y , the infant industry argument is frequently 
invoked as jus t i f i c a t i on , impl ic i t in which is the assumption that such industrie: 
require favoured treatment in the ir early stages and that this w i l l f a l l away 
as the industries ' grow up' and become competitive. In many cases i t i s c lear 
that such ac t i v i t i e s do not meet these expectations and they can only survive 3 
as long as they are protected and grow as fast as domestic demand grows. 
The above b r i e f outline of the consequences of excessive rel iance on 
import substitution po l i c i es i s in some sense a 'stereotype ' in the l i t e ra ture . 
The purpose of th is paper is to indicate, with reference to the Kenyan phar-
maceutical industry, that there are cases where industries ex is t which bear 
2. The existence of a surplus on current account can be consistent with 
an ' over-valued' exchange rate , since the exchange rate can be sustained by 
import restr ic t ions whose removal would make the balance of payments posit ion 
untenable. This i s simply the dist inct ion between the o f f i c i a l and the e f f e c t s 
exchange rate. 
3, This assumes that export potent ia l i s l imited. This issue w i l l be 
dealt with in s e c t i o n . I i . 
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most of the hallmarks of ' inappropriate' industr ia l i zat ion, but which have not 
r e l i ed substantially upon protection to establish themselves. I t must be 
stressed, however., that observations re la t ing to the pharmaceutical industry 
do not inval idate or diminish the stress la id cn trade pol icy as a determinant 
of industr ial structure in the theoret ica l and empirical l i t e ra ture , but 
merely point to other factors which are also relevant in certain cases. That 
trade pol icy plays a vary important part , even in pharmaceuticals, i s indicated 
by recent developments in the industry which w i l l be dealt within the f i n a l 
section. 
The second section of the paper comprises a description of the 
pharmaceutical industry in Kenya and deals with the nature of the Kenyan market, 
the extent to which domestic consumption is net by domestic production, the 
nature of the manufacturing firms and the i r products, the import intensity 
of production, capacity u t i l i za t i on rates within the industry and the situation 
with regard to exporting. The third section shows that domestic pharmaceutical 
production is not protected from import competition, argues that i t i s not 
cost competitive international ly and discusses explanations f o r the location 
of such industries in a country l ike Kenya. The f i na l section considers the 
relationship between trade pol icy and industr ia l structure in the context 
of the the Kenyan pharmaceuticals industry. 
I I . The Pharmaceuticals__Industry 
There are approximately 4 f i f t e e n pharmaceutical manufacturing firms 
in Kenya. Twelve of these firms have been studied, s ix of which are wholly-
owned subsidiaries of foreign companies, one of which is a j o in t venture 
between a foreign company, the Kenya Government and loca l shareholders, and 
5 
f i v e of which are wholly loca l ly owned. The industry has grown considerably 
since 1964. This can be seen from Table 1, which indicates the years in 
which firms ware established.^ 
4. A precise f igure is not given because there is some doubt about whether 
the output of one or two of the small loca l ly owned firms can be considered as 
ph armace uti cals. 
5. There are seven foreign manufacturing firms and one i s not included 
in the sample. 
6. The numbers ascribed to firms in Table 1 apply to the same firms in 
subsequent tables. 
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The expansionary trend in the industry is also indicated by the 
extent to which exports have increased. In 1964 exports of pharmaceutical 
products amounted to only £165,000, whereas in 1974 the amount was £2,640,000 
(E.A. Trade Report, 1964, 1974). Much of the expansion in exports. Was in the 
Tanzanian and Ugandan markets, which raises the question of whether such 
transactions can legi t imately be regarded as exports, as wel l as providing 
a good i l lus t ra t i on of the consequences to Kenya's industry of losirig Community 
markets. More w i l l be said about this below. 
In addition to the loca l manufactures, there are 24 foreign owned firms 
which are not manufacturing in Kenya, but which have representatives in the 
country. Only 3 of these are importing and distr ibut ing the i r own products 
and the rest have o f f i c e s in Nairobi from which they promote .their-products 
both in the loca l market and in surrounding countries. The s e l l i ng in the 
Kenyan market is l e f t to the i r agents, of which there are s ix major ones 
in Kenya, ha l f of them being loca l ly owned, 
In global terms, the Kenyan pharmaceutical market i s ins ign i f i cant . 
In 1975 the world market was worth approximately $42.7 b i l l i o n , of which the 
whole of A f r ica accounted f o r $900 mil l ion (2.1%) and Afr ica less South 
A f r i ca only $620 mill ion (1.45%). Despite the involvement in Kenya o f c i r tua l l y 
every major international drug company, in a l l cases the i r operations here 
represent less than 3% of the i r world interests . 
Estimates of the z ise of the Kenyan pharmaceutical market vary widely. 
The variation is explicable partly in terms of d i f f e r en t conceptions of what 
should be considered as pharmaceuticals. At the 'bottom' end of the market 
there is a range of mass consumption products which would be more highly rated 
in some quarters f o r the i r placebo than f o r the i r medicinal value. Also 
pract ice varies as to whether to include veterinary products and surgical 
equipment ( including bandages and dressings). 
According t o the trade s t a t i s t i c s f o r 1976, and taking S1TC 541 as 
the de f in i t ion of pharmaceutical products ( th is includes a l l veterinary products 
and sundry medical items, but excludes two small items whose, end use i s c lear ly 
cosmetic), t o t a l imports were £2.6 mi l l ion. Some imported pharmaceutical raw 
materials and f inished goods may have entered the s ta t i s t i c s as 'home use' items 
and subsequently been re-exported, but i t w i l l be assumed that a l l imports 
were e i ther f o r immediate domestic consumption or manufacture and therefore that 
5 
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a l l exports 3 t o t a l l i n g £2.9 mil l ion (£0.9 mill ion to the rest of the world 
and £2 mill ion to Uganda and Tanzania) were from domestic manufacture. In 
order t o arrive at a f i n a l f igure f o r the Kenyan market i t is necessary to 
include domestically manufactured and consumed pharmaceuticals. Estimates 
of this element vary and f igures of between 15% and 30% have been suggested. 
Taking this as a percentage on imports, and then substracting exports, i f the 
f igures is 15% the t o t a l domestic market i s £4.4 mi l l ion; i f i t i s 30%, then 
the domestic market i s worth £6 mil l ion. 
These estimates are on the low side when coup ared with popular opinion 
and i t i s impossible to reach a de f i n i t i v e conclusion. Among the d i f f i c u l t i e s 
involved in such an estimating procedure are the absence of a f irm de f in i t ion 
of pharmaceuticals, the guess as t o the proportion of domestic production in 
t o ta l consumption, double counting of imported raw materials and the assumption 
that a l l exports have been domestically manufactured. Furthermore, imports 
may not be stated at a t a r i f f and sales tax inclusive price and are quoted 
less the 33% on landed cost which usually makes up wholesale pr ices. 
The pharmaceutical market is characterized by considerable complexity. 
Part of the complexity is in t r ins i c to this industry, re la t ing t o the large 
number of s imi lar products which are avai lable , but which are d i f f e r en t i a t ed 
by brand names and display wide price variat ions. Another part of the 
complexity is a function of spe c i f i c conditions prevai l ing in Kenya, which ; 
include such considerations as di f ferences in the types of firms involved in 
the industry and di f ferences in the routes by which consumers receive the 
f i n a l product. 
A convenient dist inct ion can be made between e th ica l and 'over the 
counter' (OTC) medicines. An eth ica l drug is one which should only be 
obtainable through prescription or a dispensing medical pract i t ioner . Such 
drugs are available from licensed pharmacies, hospitals and dispensaries. 
OTC products are not considered dangerous in the same sense as ethicals and 
can be bought and sold by anyone. A further dist inction can be made between 
generics and spec i a l i t i e s , the importance of the dist inct ion being that the 
l a t t e r are known by brand name, which may or may not be subject to patent 
protect ion, and the former are known by a general name which sometimes re fers 
t o the i r contents and/or the i r e f f e c t s . Generics and spec ia l i t i e s can both 
be e i ther e th ica l or OTC medicines. 
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The most widely consumed drugs on the Kenyan market, in order of 
importance, are analgesics, ant ib io t i cs , cough treatments, antimalarials and 
anthelmintics. Of these, ant ib iot ics are v i r tua l ly the only e th ica l medicine 
(although there may be a few non-OTC products among the other categor ies ) . 
There is loca l production of a l l these drugs, with the heaviest concentration 
in OTC l ines. 
Table 2 gives an indication of the s ize (by number employed) of 
firms and the range of products that each firm is producing. With the exception 
of Firm 7, which is a jo int venture that commenced production this year, the 
foreign firms are larger than the i r local counterparts. The foreign firms 
have also tended to d i vers i f y into non-pharmaceutical l ines of production t o 
a greater extent than loca l f irms. Although i t is not shown in the table , i t 
i s noteworthy that almost a l l the foreign firms and most of the loca l ones are 
involved in importing f inished drugs ( as we l l as other f inished products, 
such as t o i l e t r i e s ) . As a percentage of t o ta l sales, f inished imports range 
up to 70%. 
Pharmaceutical manufacture in a country l ike Kenya consists bas ica l ly 
in end-stage formulation and packaging, and-stage formulation amounts in most 
cases to mixing l iquids or to granulating and tab le t t ing . Factory machinery 
usually includes such items as wet mixers, dry mixers, ovens, granulating 
machines and table t t ing machines. Packaging is mostly a manual operation. In 
some instances the f i na l formulations w i l l be no d i f f e r en t from those found in 
other parts of the world and they w i l l o f ten bear the same brand name. In other 
cases, products w i l l have brand names spec i f i c to East and Central A fr ica and 
w i l l be reformulated to suit local tastes. A good example of this i s Cofta, 
a cough syrup with a higher than average menthol content, which has consequently 
sold wel l on the loca l market. 
Foreign firms which are manufacturing in Kenya w i l l be producing the 
branded drugs of the i r own organisations fo r the most part. The higher prices 
of these drugs in re lat ion to alternatives w i l l be vindicated in terms of 
material d i f ferences between them and what others would claim were the ir 
generic analogues and also in terms of the research and development costs incurred 
in producing them in the f i r s t place. Most local firms are producing lower 
priced generics, formulated from ' rec ipes ' found in such manuals as the "Bri t ish 
Pharmaceutical Codex" and"Martindale: The Extra Pharmacopoeia". However, one 
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or two local firms have attempted to enter the spec ia l i t i es market in order 
to benef i t from brand premia. Finished drugs imported by firms and agencies 
are mostly spe c i a l i t i e s , but also include some very low priced generics, such 
as Aspirin BP from East Germany, which i s considerably cheaper than any loca l l y 
manufactured of imported equivalent. Very wide pr ice variations between large 
numbers of substitute drugs are observable, regardless of whether such drugs 
are imported or loca l ly produced, and the importance o f brand-name d i f f e r en t i a -
tion and non-price competition in this market can scarcely be over-stressed, but 
more w i l l be said about this below. 
Two other features of pharmaceuticals manufacture in Kenya are indicated 
in Table 3. There is considerable variat ion in the import intensity 
percentages given in the fourth column. The va r i ab i l i t y is accounted f o r 
pr inc ipal ly in terms of d i f f e r i n g drug content/packaging value ra t i os , since 
these are the two major elements in raw material costs. Raw materials f o r the 
drugs are v i r tua l l y a l l imported c:ad most packaging inputs are l oca l l y purchased 
and recorded in the table as local inputs., I t should be pointed out that 
treat ing packaging materials as local inputs understates the import intensity 
of production, since several packaging materials, including f o i l , t in and boxes, 
are very import intensive themselves. F inal ly , the accuracy of these import 
content f igures i s l imited by the fac t that they are averaged estimates over 
a wide range of d i f f e r en t products. 
The capacity u t i l i z a t i on rates of the industry show that no f irm is 
operating more than a single eight-hour s h i f t and with5_n that s h i f t , u t i l i za t i on 
7 
rates are as 30% in one case and no higher than 75%. These percentages are 
based on machine usage rates. I t has also been asserted that Kenya's tab le t t ing 
f a c i l i t i e s are only being used to 30% of the i r capacity on a 24 hour basis. 
Part o f the explanation given f o r these rates was that the manual packaging 
operations tended to create bottlenecks on production l ines , but the major 
constraint to greater u t i l i za t i on was considered to be market demand. This 
l a t t e r point was borne out by the observation by several managers that u t i l i za t i on 
had dropped substantial ly since the Tanzania border closure. 
The 75% f igure f o r Firm 7 should be treated with circumspection, since 
i t i s almost certainly an overstatement. 
- 8 IDS/WP 329 
The market f o r pharmaceuticals consists of the public sector 
(government hospitals , dispensaries and loca l author i t ies ) and the private 
sector (served by pharmacies, dispensing doctors and private hosp i ta ls ) . 
The public sector accounts fo r approximately 75% of pharmaceutical consumption 
in volume, but probably less in value because of large price di f ferences 
between generics and spec i a l i t i e s , the l a t t e r being bought and sold predo-
minently in the private sector. The public sector deals with about 80% of 
the population, the remainder re ly ing on prescribing and dispensing doctors 
and on mission hospitals. 
Wherever possible, the public sector w i l l buy generic ethicals and 
OTC medicines at a considerably lower price than the i r branded substitutes. 
Clearly f o r slow moving and more sophisticated drugs, this choice w i l l 
sometimes not ex i s t . A l l public sector purchases are made by tender. In the 
private sector non-dispensing doctors w i l l usually prescribe by brand name. 
Dispensing doctors, on the other hand, w i l l tend to vise low cost drugs, 
since the i r consultancy fees w i l l usually include treatment costs. Mission 
hospitals w i l l usually try to buy generics where possible. 
Table M- shows the percentages of t o t a l pharmaceutical products exported 
botH before &nd a f t e r the" Tar-^ania border closure, as we l l as current 
destinations of exports. The export percentages f o r the period before the 
Tanzania border closure are based on annual f igures and the post border 
closure f igures are in some cases based on actual exports f o r s ix months and 
in others are project ions fo r the f u l l year fo l lowing the closure. I t i s c lear 
from the table that the only markets available to Kenya are in surrounding 
African countries. I t i s also clear that the Tanzania market was an important 
one and i t s loss has had a marked impact on the industry. 
On the whole, foreign companies are exporting proportionately more 
than the ir loca l counterparts. Firms 8, 9, 11 and 12 have no real interest 
in exporting and any export sales that they make are a response to direct 
enquiries and usually depend on personal or family connections. 
i 
There are certain considerations which some firms w i l l take in to 
account, i r respect ive of government po l i cy , in deciding where and how much 
to export. This is generally more true of international companies than loca l 
ones. In part icular , an international company which decides to locate manufac-
9 -
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turing f a c i l i t i e s in a country l ike Kenya w i l do so as part of a global 
strategy and therefore w i l l have already decided which markets are to be 
served from a part icular plant. In the case of these s ix international f irms, 
i t is pol icy not to export from Kenya t o markets other than those in East 
and Central A fr ica (except in special circumstances) and therefore there i s a 
bu i l t - in l imit t o the responsiveness of these firms to export incentives. 
Another factor which mil i tates against vigorous exporting e f f o r t s 
concerns the desire on the part of firms to consolidate the i r positions in the 
domestic market before looking at foreign market opportunities. The manager 
of one international f i rm, f o r example, stated that his company was not 
interested in exporting unt i l 60% of t o ta l capacity had been absorbed in 
domestic sales. The explanation for this pol icy was that neither the pro-
f i t a b i l i t y nor the s t ab i l i t y of foreign markets could be guaranteed and commercial 
prudence required primary ( and possiblv so l e ) re l iance on the home market. 
Not only does such a po l i cy , i f i t is r i g id l y adhered to , impose an upward 
l imi t on the s i ze of an investment that w i l l be undertaken, but i t also 
considerably reduces the wil l ingness of a f irm to respond to export incentives. 
A further corporate pol icy consideration which can over-ride export 
encouraging e f f o r t s by government is the desire to locate manufacturing as 
near as possible to the market. In a typ ica l l y protected industry such a 
location decision may be designed to overcome import restr ic t ions in a country 
( ' t a r i f f jumping'). In pharmaceuticals, i t is not c lear that this pol icy is 
so a t t rac t i ve , but the manager of one firm stated that i t was company pol icy 
to use Kenya as a base f o r establishing a posit ion in part icular African markets 
and that once this had been done, manufacturing f a c i l i t i e s would be set up in 
these countries. To the extent that such a practice is pursued, any Kenyan 
export success in pharmaceuticals w i l l be ephemeral. 
I f there are no pr ior consideration which dictate export quantities 
and/or destinations, then re la t i ve p r o f i t a b i l i t i e s of domestic and fore ign 
sales w i l l be an important determinant o f export performance. There is a 
large number o f factors which have to be considered in re la t i ve p r o f i t a b i l i t y 
calculations, including domestic price control regulations, the 10% export 
compensation, and the price e l a s t i c i t y of demand in d i f f e r en t markets (an 
aspect of foreign market conditions which w i l l not be considered here) . 
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Price control regulations were introduced in the early 1970's (on 
the majority of the currently controlled items) and there is some divers i ty 
in the interpretation of the ir intention and e f fect iveness among manufacturers. 
Basical ly , price control is supposed to apply to a l l consumer goods and to 
many o f the i r domestically purchased inputs. The prices of some staple or 
mass consumer items are gazetted and subject to stringent control . Other 
items are control led at the price l eve ls prevai l ing when the regulations were 
introduced. Pharmaceuticals f a l l into the l a t t e r category. In order to 
raise prices an application must be made to the Price Control ler, giving 
deta i ls of operations over several years and demonstrating that r is ing input 
costs have eroded p r o f i t margins. The application procedure is time consuming 
and the thoroughness with which applications aire considered leads to long 
delays, so much so that in 1975 the regulations, were changed. The new regulations 
state that i f there has been no reply from the Price Controller to an application 
within 30 days, then the price increase can be implemented. 
Several manufacturers question the l ega l i t y of price control regulations 
which are not announced in the Kenya Gazette and f i v e f irm managers interviewed 
e i ther stated or implied that they put the i r prices up anyway when r is ing input 
costs made i t necessary. Almost a l l the managers f e l t that p ro f i t s from 
domestic sales had been eroded by price control even i f they were not s t r i c t l y 
adhered to , since the leve ls and frequency of price r ises were inhibited by 
the existence of the regulations. To the extent that the Price Control ler 's 
decisions are variable, and the reactions of manufacturers also vary, the 
regulations w i l l have a d i f f e r en t i a l e f f e c t , on firms within an industry and 
w i l l be a d istort ing factor in the sense of rewarding or penaliz ing a c t i v i t i e s 
independently of any systematic c r i t e r i a . 
10% export compensation was introduced in 1974 f o r manufactured 
goods. The 10% is calculated on f . o .b . value and is designed to go some way 
in o f f s e t t i n g the anti-export bias of the trade pol icy regime. Most of the 
firms were claiming the compensation, but i t i s noteworthy that only one 
manager stated that i t resulted in greater export volumes. In this case the 
greater volume arose as a result o f p r o f i t inducement rather than through increase 
demand as a consequence of lower pr ices. A l l the other firms regarded the 
compensation as a windfa l l gain which did not influence marketing decisions. 
The reasons given f o r seeing the compensation in this l i ght were that there 
were delays of up to four months in receiving i t and that there was too much 
uncertainty regarding whether i t would be received and how long the Treasure 
would apply. 
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Four f irm managers stated that a unit exported was more pro f i tab le 
than a unit sold domestically, and two of them cited price control regulations 
as one explanation f o r this . However, none of the managers gave the impression 
that this constituted a decisive factor in determining market destination. 
Other reasons given f o r greater export p r o f i t a b i l i t y were, f i r s t l y , that 
domestic distribution nosts incurred in the Kenya market were d i f f i c u l t to 
pass on to the consumer, whereas in export markets they were not incurred 
at a l l . Secondly, i t was suggested that in soma of the export markets i t was 
much easier to be a price maker. F inal ly , agreeing to the practice of over-
invoicing exports to certain markets and banking the balance in Kenya means 
higher s e l l i ng prices than would otherwise be the case. 
A f i na l point which should be made in relat ion to foreign firms and 
exporting, and which has implications for other industries besides pharmaceuticals, 
i s that these firms can frequently ca l l upon alternat ive sources of supply 
to serve a spec i f i c market. Following the Tanzania border closure, theparents 
of foreign firms who were s e l l i ng in Tanzania cal led upon other subsidiaries 
or other parts of the group to supply that market. One analgesic product in 
part icular has increased i t s share of the Tanzanian market to such an extent 
( large ly because competition from loca l ly owned manufacturing firms was eradicated) 
that the Kenyan subsidiary producing the product would have to expand i t s 
plant i f i t had to supply that market again without external assistance. The 
ab i l i t y of foreign firms to switch supply sources in this manner ( and not 
lose out in the aggregate) , when they are not re ly ing on loca l raw materials, 
i s a further reason why i t would be optimistic to expect industries of this 
i l k (pharmaceuticals) t o contribute to foreign exchange earnings substantial ly 
in any sustained way. 
The general impression that exporting is in most cases regarded as a 
secondary and re la t i v e l y unimportant ac t i v i t y was explained by firm managers 
in terms of the l imited nature of the markets, s t i f f foreign competition, 
uncertainty regarding p o l i t i c a l situations and commercial po l i c ies in importing 
countries and adequate p ro f i t s from domestic sales. 
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I l l y . Protection and Competitiveness 
Without attempting detai led e f f e c t i v e protection calculat ions, which 
in aAy case would lose some of the i r usefulness in the absence of considerable 
disaggregation within the pharmaceuticals sector, there does not seem to be 
any doubt that pharmaceuticals manufacture is not protected. In f a c t , 
pharmaceutical production is anti-protected as a result of the existence of 
a t a r i f f ano\naly and from protection of some of the domestically purchased 
inputs» 
A l l imported pharmaceutical products, with the exception of gripe 
water (which is on quota), were not, unt i l very recently, subject to any 
quantitat ive res t r i c t ions . Furthermore, many f inished pharmaceuticals come in 
duty f r ee . A l l generics made to BP, USP or BPC standards, a l l in jec tab le > 
f lu ids , a l l anti-malarials, a l l anthelmintics and a l l products ruled duty 
free by the Director of Medical Services are free of t a r i f f charges. The 
t a r i f f anomaly re ferred to above arises from the fact that organic chemicals 
being imported under BTN 29.01/450, some of which are used in pharmaceutical 
msaufacture, at tract a duty of 20% ad valorem. Also, some imported packaging 
mate r ia l s , including amber* glass (which is loca l ly unavai lable) , are subject 
to t a r i f f s . 
One factor which must be mentioned, and which may a f f o rd a degree 
of protection to local manufacture,relates to the fact that approximately 
75% of a l l drugs sold in Kenya are purchase by government tender. I t i s 
not c lear what the government's tendering pol icy i s , or whether i t is 
consistent, but i t has been suggested that loca l manufacturers' o f f e r s are 
given spec ia l consideration, to the extent of 10% to 20% in pr i ce , provided 
the quality i s acceptable. There is some doubt that such a pol icy ex i s t s , 
or that i f i t does i t w i l l always apply. Even i f i t does, 10% to 20% w i l l 
be an inadequate margin in some cases, such as in analgesics. Furthermore, 
such a concession would not protect firms which are engaged in producing 
spec ia l i t i e s or other drugs f o r the pr ivate section of the market. 
The f i r s t consideration which mil i tates against the poss ib i l i t y that 
domestic pharmaceuticals manufacture is cost competitive internat ional ly 
i s the existence of the t a r i f f anomaly. I t is not c lear how the anomaly arose 
o r i g i na l l y , but "one explanation may be that some imported pharmaceutical raw 
materials, such as menthol, edible gelat in and talcum powder have other end 
uses as we l l , as do some of the packaging materials. 
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Two other pol icy induced factors which make inroads on the competitive-
ness of domestic manufacture are import l icensing, and in certain cases, sales 
tax procedures. Almost a l l pharmaceutical raw materials are on Open General 
Licence, but the processing of import licenses is sometimes a lengthy procedure 
and a f f e c t s the attitudes of managers as to how much input stock should 
be held. Only two out of twelve managers did not think that the i r stock 
holding costs were raised by import l icensing procedures and the i r reasons 
were that they had cash flow problems which meant that they could not hold 
the amount of stock they wanted to in any case and that they were dealing 
with slow moving items subject to seasonal demand, so they would hold a l l they 
could a f f o rd to. The other ten firms asserted that they bore addit ional stock 
holding costs, part ly because of time f luctuations, and the attendant uncer-
t a in t i e s , of import l icence procedures. There are also addit ional costs in 
terms of the necessity of greater forward planning times and the consequent 
inab i l i t y to buy in when prices are most favourable; furthermore, i t i s sometimes 
necessary to a i r f re ight raw materials, at high cost, t o avoid stock shortages 
and there is occasionally a further cost i f a consignment has to be broken down 
into lots of less than Shs.M-.}£)00 in order t o avoid import l icensing altogether. 
I t might be argued that importers of f inished pharmaceutical products face 
s imi lar problems , but the e f f e c t s are unlikely to be so far-reaching:since, theirs 
is only a warehousing and s e l l i ng operation and they are mostly buying on an 
agency basis at pre-arranged pr ices . Thus i t does not seem unreal ist ic t o 
assume that import l icensing procedure costs are higher f o r loca l manufacturers 
then importers, although to the extent that both manufacturers and importers 
are a f f ec ted , the competitive disadvantage t o the former is smaller. 
The sales tax issue is less straightforward, part icular ly as the 
regulations have changed recent ly , but there are certain imported pharmaceutical 
raw materials, which e i ther f a l l into a part icular BTN category on which sales 
tax i s automatically lev ied or e lse are considered as both raw materials and 
f i n a l goods and therefore subject to sales tax. In some cases sales tax 
may also be lev ied on domestic raw materials. Since sales tax is not 
chargeable on industr ia l raw materials, a f irm which has been charged w i l l 
have t o undertake a reclamation procedure, which frequently takes up to three 
months or more and entai ls costs both in terms of t i ed up working capi ta l 
and administration. 
Apart from the pol icy considerations, low capacity u t i l i za t i on rates ' 
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( lower presumably than those prevai l ing in many competing countries) 
inevitably mean higher unit production costs. The pro l i f e ra t i on of numerous 
product l ines , many of them being produced on the same machinery, means that 
certain scale economies cannot be taken advantage of and once again this 
raises unit costs. I t is d i f f i c u l t t o make accurate international comparisons 
of input costs, but in the case of pharmaceuticals, the need to do so i s 
part ly obviated by the inport intensity of Kenyan manufacture. I f the somewhat 
heroic assumption is made that the import element, whether i t is landed in Kenya 
as raw materials or as part of a f inished good', i s comparable in cost, then 
i t i s reasonable t o assume that the dominance of this input in f i n a l cost w i l l 
ensure that Kenyan manufacture does not have an input price advantage over 
competing imports. 
The only consideration which could mi l i tate against this conclusion 
relates to re la t i ve labour costs. The general f ee l ing in the industry is that 
while labour i s considerably cheaper in Kenya than in Eurone and the United 
States, the advantage is more than o f f s e t by other cost factors. The only 
direct evidence that was obtained related to the production of an analgesic in 
Kenya and in the UK. The f igures given below are inclusive of t a r i f f s , taxes 
g 
and transport and the UK has a 15% cost advantage. 
Kenya UK 
Raw materials 56 35 
Packaging 4 8 35 
Labour 11 22 
Extra non-comparable packing cost — 8 
115 100 
UK's 15% cost advantage w i l l be added to by the 8 units going in additional 
packaging. I t w i l l almost certainly be further added to by a consideration 
of inputed overheads, given re la t i ve capacity u t i l i za t i on rates. Whatever 
the f i n a l cost advantage to the UK, i t i s hardly l ike ly t o be o f f s e t by the 
costs of transporting the f inished drug from the UK to Kenya. For a l l of the 
above reasons, i t i s suggested that pharmaceutical manufacturing in Kenya i s 
not as low cost or e f f i c i e n t as i t i s in the major manufacturing centres of 
the world, the same centres which are supplying the Kenyan market alongside 
domestic manufacturers. I f this i s the case, and there is no insulation from 
import competition, then al ternat ive explanations of the existence and continued 
8. This is a 1976 comparison, using the exchange rate prevai l ing at that 
time. 
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survival of pharmaceutical manufacturing in Kenya must be sought. 
A explanation of this situation must turn on spec i f i c conditions 
prevai l ing in the market. The most obvious point here, which has already been 
alluded to , i s that there is a marked absence of price competition in the 
pharmaceuticals market. This is r e f l e c t ed in considerable product d i f f e r en t i a -
t ion and heavy advertising expenditure, part icular ly in OTC l ines. According 
to the Corcorran and Ty r e l l Advertising Review (1975 and 1976), ejqjenditure 
on analgesics advertising alone accounted f o r 3.2% and 2.7% of t o t a l spending 
in 1975 and 1976 respect ively. One manufacturer claims that approximately 
10% of the r e t a i l price of his analgesics is accounted f o r by advertising 
expenditure. Bearing in mind that distribution mark-ups are over 33%, this 
makes advertising a s ign i f i cant cost item f o r manufacturers. 
A cursory look at the anagesics market v e r i f i e s the lack of pr ice 
competition. Any pharmacy w i l l have 20 or more OTC analgesics in stock. 
Broadly speaking, an analgesic w i l l contain some or a l l of the fo l lowing active 
ingredients (among others ) : - a ce t y l sa l i c y l i c acid, ca f fe ine and paracetamol. 
These ingredients w i l l be found in varying proportions and quantities and the 
type of packaging used w i l l also vary, so direct r e t a i l price comparisons 
must be treated with caution. Nevertheless, i t seems very unlikely that the 
price di f ferences are adequately explained by these factors. Two examples 
w i l l s u f f i c e : Dawasprin ( l o ca l manufacture, packed in f o i l ) r e ta i l s at Shs.3/20 
f o r 20 tab le ts , whereas Boots Aspirin ( l o ca l manufacture, packed in a b o t t l e ) 
r e ta i l s at Shs.3/4-0 f o r 100 tab le ts . The di f ference of a factor of nearly f i v e 
can scarcely be accounted f o r by di f ferences in packaging and ingredient costs\ 
Panadol ( l o c a l manufacture, packed in a bo t t l e ) s e l l s at Shs.33/- f o r 100 tablets 
whereas Paracetamol (imported, packed in a bo t t l e ) s e l l s at Shs.15/- f o r 
100 tab le ts . This second example further i l lus t ra tes the presence of import 
competition and also the price di f ferences which exist between generics and 
spec i a l i t i e s . (Panadol and Paracetamol are v i r tua l ly the same thing) . 
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The situation re lat ing to e th ica l medicines is complicated by the 
fact that they are not f o r sale on the open market and medical pract i t ioners 
w i l l be substantially responsible f o r determining market shares. Nevertheless, 
there i s considerable product d i f f e rent ia t i on and price variation in this 
section of the market as wel l . Taking ant ib iot ics as an example,there are 
s ix or seven 'broad spectrum' ant ib io t ics (including te tracyc l ines , 
sulphonamides, o en i c i l l i n s , a p i c i l l i n s , erythromycins and chloramphenicols) 
and i t is generally considered that these formulations w i l l serve over 70% 
of the ant ib io t ic needs of consumers. However, there are over 35 separate 
branded ant ib iot ics available on the market, only a small portion of which 
includes slow moving specia l ly formulated drugs. 
Product d i f f e rent ia t i on combined with price var iab i l i t y between 
substitutable drugs is easy to maintain, given the way the market f o r phar-
maceuticals is fragmented;' The practice of ident i fy ing and prescribing drugs 
by brand name ensures a lack of awareness o f , or interest in , pr ice di f ferences 
or even of the ava i l ab i l i t y of substitutes in some cases. This is true of 
the government tender as we l l , where an inv i ta t ion to tender sometimes amounts 
to no more than an o f f e r to buy a part icular drug from a part icular producer. 
Consumer attitudes generally also play the ir part in supporting 
product d i f f e r en t i a t i on . Attitudes to drugs are characterized by conservatism 
and habit . I f a consumer is accustomed to a part icular brand, he is unlikely 
to change or experiment with cheaper products, especial ly i f he has been 
persuaded that each drug has exclusive character ist ics. Furthermore, i t 
has been suggested that a certain consumer 'pervers i ty ' i s common in this 
market, whereby a predi lect ion fo r higher rather than lower priced drugs i s 
displayed, in the b e l i e f that r e la t i ve prices r e f l e c t quality and e f fect iveness 
Heavy product d i f f e r en t i a t i on , which sustains price va r i ab i l i t y 
between drug substitutes, adequately explains how variable p r o f i t rates, 
input cost structures and e f f i c i ency leve ls can be accommodated within this 
market. The question remains as to why, in the absence of trade impediments 
and raw material sources, firms choose to locate in a r e l a t i v e l y high cost 
area rather than to continue to supply from overseas plants. The question i s 
relevant only to the international f irms, f o r whom such a choice ex is ts . 
The existence o f non-price competition together with wide price 
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va r i ab i l i t y suggests high p r o f i t margins. One manager stated that his 
experience in industry had convinced him that p ro f i t s in the pharmaceutical 
industry worldwide were much higher than in most sectors and that p ro f i t s 
in eth ica l l ines averaged at around 65% of s e l l i ng pr ice . In a high p r o f i t 
industry i t is easier to carry extra costs arising from suboptimal location 
On the other hand, i f i t i s assumed that foreign firms are p r o f i t maximizing, 
then what appears as a suboptimal decision from the point o f view of 
comparative input costs may not be suboptimal at a l l . 
Where there is product adaptation to suit local conditions, such 
adaptation could possibly be more eas i ly undertaken in a location near the 
market rather than in t rad i t iona l locations. I f the adaptation is considerable, 
or i f the adapted product is only a small share of to ta l output in a part icular 
l ine , then i t may in fact prove lower cost to set up manufacturing in what 
would otherwise be a high cost location. 
Three managers explained the i r f irms' decisions to locate in Kenya 
as a means of acquiring a larger market share. The reasons given f o r be l iev ing 
that this would be the case included the poss ib i l i t y that government pol icy 
would discriminate in the i r favour, but more w i l l be said of this in the 
next section. Another reason given was that l oca l manufacture was a good 
s e l l i ng point. This is more l ike l y to be so i f i t i s an international ly known 
brand that is being loca l ly produced. I f i t i s not, local production could 
be disadvantageous on account of i r ra t iona l consumer preference f o r imported 
goods. Some managers stated that i t was simply corporate pol icy to invest in 
manufacturing ac t i v i t i e s around the world. Such a pol icy i s pursued f o r reasons 
of corporate 'image' or 'pres t ige ' and may also be connected with risk 
spreading. 
Table 2 shows c lear ly that most of the foreign manufacturing firms 
are involved substantially in non-pharmaceutical production l ines. A l l of the 
items l i s t ed in the fourth column of Table 2(with the exception of veterinary 
products) are subject to quantitative import restr ic t ions ( e i ther quotas or 
bans) as we l l as to t a r i f f protect ion. They represent typ ica l import substituted 
9. I t is not always so clear that high p r o f i t margins ex is t where there is 
heavy product d i f f e rent ia t i on and standardized prices. In the Kenyan paint 
industry, f o r example, where there is a price agreement between seven manu-
facturers, prices have been kept below the government price control led e e i l i ng 
in the be l i e f that contravention o f the agreement w i l l be less tempting as a 
result . 
- 18 - IDS/WP 329 
manufacture and have l imited export potent ia l . In these cases there is an 
obvious pol icy induced locational advantage, and bearing in mind the market 
s ize l imitat ion, i t does not seem inconsistent f o r these firms to be involved 
also in related production (pharmaceuticals in this instance), which often 
requires the same machinery f o r manufacture. I t should also be remembered 
that a l l o f these firms are involved in the importation of f inished goods. 
Final ly , mention should also be made of the transfer pr ic ing issue 
and foreign firms. I t has been shown that transfer pr ic ing practices were 
r i f e in the pharmaceuticals ( and other) industries in South America (reported 
in La l l (1973)). I t i s d i f f i c u l t to obtain evidence of t ransfer pr ic ing , but 
there i s no prima fac ie reason to assume that the practice does not ex is t 
in other parts of the developing world. However, the point to be made here is 
that i f the Kenyan pharmaceutical industry is pervaded by this kind of p r o f i t 
remission, i t does not help t o explain the or ig ina l location decision, since 
in this part icular case, there i s no impediment to generating such p ro f i t s 
on the sale of f inished goods. 
IV. Conclusion 
I t has been argued that pharmaceuticals manufacture in Kenya displays 
a l l the features of an import substituted infant industry with a preference 
f o r continued juven i l i t y . I t is the kind of industry which i s not (now or 
in the foreseeable future) international ly cost competitive. I t changes the 
composition of imports rather than making s ign i f i cant foreign exchange savings 
and i t does not appear to be we l l placed to earn foreign exchange in any 
quantity on a sustained basis. Yet on the face of i t the industry did not 
establish i t s e l f in response to the usual pol icy induced incentives. Explana-
tions f o r this apparent paradox have been sought both in terms of the ab i l i t y 
of firms to establish themselves in the absence of protection against imports 
and in terms of the i r wil l ingness to do so. The explanations have turned 
primarily on the scope f o r product d i f f e rent ia t ion and the fragmented nature 
of the market. 
Having established that trade pol icy did not play i t s customary role 
in spawning the pharmaceutical industry, the question arises as to the implica-
tions of this situation f o r the assumed nexus between trade pol icy and 
industr ia l structure. In the f i r s t place, i t should be noted that investments 
in f l edge l ing manufacturing a c t i v i t i e s are sometimes of a pre-emptive nature. 
In a country where protection from imports i s frequently sought and nearly as 
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frequently given, investors may almost take i t f o r granted that once 
manufacturing has commenced, government w i l l f ind the protect ionist clamour 
i r r e s i s t i b l e . There is some indication of this kind of thinking in the 
comments of three managers reported in the previous section. 
Furthermore, i t has become clear in recent months that pharmaceuticals 
manufacture is to be protected a f t e r a l l . The most recent, and by f a r the 
largest pharmaceuticals factory was set up with the express understanding that 
protection would be forthcoming. Within i t s product range, this factory has 
the capacity to serve a market of 80 mill ion people. I t appears that the 
target market was to include Uganda and Tanzania and that insta l l ed capacity 
would s t i l l leave room f o r exporting. In these circumstances, i t is hardly 
surprising that the f irm is anxious to guarantee as large a market as possible. 
I t i s also noteworthy that i t i s in the nature of the industry, because of 
consumer price insens i t i v i t y , that the protection has to be quantitative rather 
than by t a r i f f . As would be expected,; no import duties have been imposed on 
pharmaceuticals, but a l i s t of some local ly produced drugs has been compiled 
and none of these drugs, or what may be judged as the i r substitutes, can be 
imported. 
This recent development does not a l t e r the fact that pharmaceutical 
manufacture in Kenya pre-existed protection by some ten years or more, and 
here is one case where trade pol icy i n i t i a l l y played a less decisive role 
in this type of investment decision than i t usually does. F inal ly , the 
experience of the pharmaceuticals sector raises the question o f whether, in 
an economy already over-burdened with, administrative interventions, which are 
sometimes cumbersome and counter-productive, there i s not room f o r one more; 
namely, a system of industr ia l l icensing. 
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TABLE 1 - FIRM OWNERSHIP & YEAR OF COMMENCEMENT 






















" 19 71 
" 1970 
" 1961 
TABLE 2 - NUMBER OF EMPLOYEES AND PRODUCT RANGE 
Foreign/Local 
Local 
FIRM NUMBER EMPLOYED MANUFACTURED PHARMACEUTICAL PRODUCTS 














Ant ib iot ics , vitamins, cough 
treatments, sundry (75%) 
Ant ib iot ic capsules, sundry(20%) 
Cough treatments, anthelmintics, 
analgesics sundry. 
Analgesics5 sundry (40.5%) 
Linaments, medicated soap (100%) 
Analgesics, diarrhoea,ant ibiot ics, 
vitamins, t ranqu i l l i z e rs , sundry (100%) 
OTHER MANUFACTURED 
PRODUCTS 
To i l e t r i e s (43%) 
Baby foods (25%) 
Agricultural 






To i l e t r i e s (55%) 
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Table 2 Continued 
FIRM NUMBER EMPLOYED 
27 
MANUFACTURED PHARMACEUTICAL PRODUCTS OTHER MANUFACTURED 
(with percentage of t o t a l output in PRODUCTS 
parenthesis) 
Ant imalar ia ls , cough treatments, 
balms, analgesics (90%) 
T o i l e t r i e s (10%) 
15 Cough treatments, ointments, linaments 
(100%) 
10 23 Diarrhoea^ cough treatments, anthelmi-
n t i c s , vitamins, an t i b i o t i c s , 
antimalarials (100%) 
11 17 an t i b i o t i c s , antihistamines, cough 
treatments, analgesics, antima-
l a r i a l s (100%) 
12 24 Analgesics, ant imalar ia ls , cough 
treatments, sundry (100%) 
TABLE 3 - CAPACITY UTILIZATION 8, IMPORT INTENSITY 
FIRM NO OF SHIFTS WORKED MACHINE CAPACITY 
UTILIZATION RATE 
%0F IMPORTS IN VALUE 
OF RAW MATERIALS 
1 1 60% 85% 
2 1 55% 40% 
3 1 45% 60% 
4 1 65% 90% 
5 1 60% 40% 
6 -1 n/a n/a 
7 1 75% 76% 
8 1 50% 75% 
9 1 60% 35% 
10 1 30% 70% 
11 1 60% 40% 
12 1 50% 85% 
22 - IDS/WP 329 
TABLE M- - PHARMACEUTICAL. EXPORTS 
CURRENT EXPORTS AS A EXPORTS AS A % OF CURRENT EXPORT 
% OF OUTPUT OUTPUT BEFORE DESTINATIONS 
TANZANlAN BORDER 
CLOSURE 
15% 80% Somalia, Ethiopia 
18% i+0% Uganda, Zambia, Malawi 
5% n/a Uganda, Somalia ; 
60% n/a Zambia,Uganda, 
Ethiopia, Somalia 
31% 64% ^ Zambia, Malawi 
5% 30% Somalia 
10% - Burundi, Ethiopia 
3% 10% Uganda, Samalias 
Zaire 
65% 80% Uganda, Somalia, 
Rwanda, Burundi, 
Zaire, Zambia. 
7% 20% Malawi, Zaire, 
Sudan. 
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